Chardan Capital Boosts Forte Biosciences (NASDAQ:FBRX) Price Target to $64.00

by · The Cerbat Gem

Forte Biosciences (NASDAQ:FBRX – Get Free Report) had its target price upped by analysts at Chardan Capital from $3.00 to $64.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Forte Biosciences Stock Down 0.2 %

Shares of NASDAQ FBRX traded down $0.01 during trading on Friday, reaching $5.57. 11,205 shares of the company traded hands, compared to its average volume of 4,489. Forte Biosciences has a 52-week low of $4.11 and a 52-week high of $21.25. The firm has a 50 day simple moving average of $5.53 and a 200-day simple moving average of $2.26. The stock has a market capitalization of $8.13 million, a PE ratio of -0.32 and a beta of 0.04.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11). As a group, research analysts predict that Forte Biosciences will post -22.5 EPS for the current year.

Forte Biosciences Company Profile

(Get Free Report)

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.

Featured Articles